Sionna Therapeutics Inc., a biopharmaceutical company focused on advancing treatments for cystic fibrosis, announced positive results from Phase 1 clinical trials for its NBD1 stabilizers, SION-719 and SION-451. These trials, conducted in healthy volunteers, demonstrated that both stabilizers were generally well tolerated and achieved desired pharmacokinetic targets, supporting their potential as add-ons to current standard care or in combination with other modulators. Sionna plans to progress SION-719 into a Phase 2a proof-of-concept trial for cystic fibrosis patients and SION-451 into a Phase 1 dual combination trial, both set to commence in the latter half of 2025. The company aims to release topline data from these trials by mid-2026.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。